Overview
Balance Sheet
Cash Flow
Growth Analysis
2024
2023
2022
2021
2020
Profitability Metrics
Gross Margin
100.00%
Operating Margin
88.89%
Net Margin
46.81%
Efficiency Metrics
Revenue per Expense Ratio
7.39
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
88.89%
Income Tax Rate
1.43%
EPS
2.0500000000
Balance Sheet Analysis
Current Ratio
114.85
Cash Ratio
114.85
Working Capital
$31.99M
Debt to Equity
1.02
Debt to Assets
49.69%
Equity Ratio
48.51%
Cash Flow Analysis
Operating Cash Flow Ratio
56.50%
Free Cash Flow Ratio
56.50%
CapEx to Revenue
0.01%
Dividends Paid
$102.93M
Stock Buybacks
$1.06M
Total Shareholder Returns
$103.99M
Cash Position Change
49.52%
Key Takeaways (2024 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 6.68%
Detailed Growth Metrics
Core Performance
Revenue
189.87%
Net Income
151.98%
EPS
86.36%
Operating Income
129.68%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
14.55%
Operating Cash Flow
17.00%
Free Cash Flow
17.10%
Balance Sheet Health
Assets
23.78%
Debt
21.39%
Book Value per Share
-5.67%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
6.68%
Shares Outstanding
35.69%
Long Term Trends
3Y Revenue/Share
14.87%
5Y Revenue/Share
49.70%
3Y Dividend/Share
20.59%
5Y Dividend/Share
-0.62%